Suggestions
Robert Hennessy
Life Sciences retained executive search serving CDMO, Biologics, Orphan Drugs, Specialty Pharma, Big Pharma
Robert Hennessy: Founder and CEO of The Hennessy Group
Robert Hennessy is the founder, CEO, and lead search consultant of The Hennessy Group, a boutique executive search firm dedicated to connecting life sciences companies with their next great leaders.1234 With over 30 years of experience in the executive search industry, Hennessy has built a successful career in both small and large firms, including starting and building a new office for Korn/Ferry International and helping launch a global search firm with specialty practices across North and South America, Europe, and Asia.3
Founded in 1999, The Hennessy Group has a 94%+ success rate in placing nearly 600 leaders in the life sciences industry, with an average of one placement advancing to President or CEO every 8 months.24 The firm focuses on executive recruiting for pharmaceuticals, contract development and manufacturing organizations (CDMOs), biologics, orphan drugs, specialty pharma, and other life sciences companies.24
Hennessy's approach emphasizes building strong relationships with candidates through extensive personal interaction, including many hours of video conferencing, to assess their fit and leadership potential.2 This attention to detail and candidate care has helped The Hennessy Group achieve its high success rate and maintain a small, dedicated recruiting team.24
Under Hennessy's leadership, The Hennessy Group has been recognized as a top executive recruiting firm by Forbes in 2018 and 2019.25 The firm has offices in Philadelphia, Los Angeles, and Park City, Utah, and entered a partnership with Norland Associates, Ltd. in 2018 to expand into the East Asian market.2
Highlights
We are looking for Senior Medical Directors in both biopharmaceuticals and medical devices. Our client has enjoyed 21 consecutive quarters of positive adjusted EBITDA culminating in a record 2nd quarter in 2022. They are on track to deliver their 8th consecutive year of positive adjusted EBITDA. The company expects to achieve operating margins that exceed 50% by end of 2024. With their proprietary technology, the company has the opportunity to expand into new therapeutic areas including gene therapy, cardiac care, diabetes, endocrinology and psychiatry. They have a comprehensive and robust clinical development plan which is enabling them to expand into new areas for both drug and medical device therapies. While NJ is a primary location, additional sites include S. CA and FL. Remote opportunities are possible for ideal candidates. Senior Medical Directors should apply for consideration at the Executive Director level.
We are looking for an experienced SVP, Head of Corporate Development for a top 20 CDMO. This person will execute the M&A portion of our client's growth strategy. #hiring #mergersandacquisitions #lifesciencejobs https://lnkd.in/eWZ_hsS
